SI2838998T1 - Egfr in ros1 pri raku - Google Patents

Egfr in ros1 pri raku Download PDF

Info

Publication number
SI2838998T1
SI2838998T1 SI201330902T SI201330902T SI2838998T1 SI 2838998 T1 SI2838998 T1 SI 2838998T1 SI 201330902 T SI201330902 T SI 201330902T SI 201330902 T SI201330902 T SI 201330902T SI 2838998 T1 SI2838998 T1 SI 2838998T1
Authority
SI
Slovenia
Prior art keywords
inhibitor
ros1
egfr
polynucleotide encoding
polypeptide
Prior art date
Application number
SI201330902T
Other languages
English (en)
Inventor
Katherine Eleanor Crosby
Rimkunas Victoria Mcguinness
Matthew Ren Silver
Herbert Haack
Original Assignee
Cell Signaling Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology, Inc. filed Critical Cell Signaling Technology, Inc.
Publication of SI2838998T1 publication Critical patent/SI2838998T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Claims (12)

  1. EGFR IN R0S1 PRI RAKU PATENTNI ZAHTEVKI
    1. Metoda, ki obsega: odkrivanje v biološkem vzorcu pri človeškem bolniku, ki ima ali obstaja sum, da ima raka prisotnost ROS1 fuzijskega polipeptida, ki ima ROS1-kinazno aktivnost ali polinukleotid, ki kodira isto; in odkrivanje v biološkem vzorcu prisotnosti mutantnega EGFR polipeptida ali polinukleotida, ki kodira isto.
  2. 2. Metoda po zahtevku 1, kjer je vzorec iz pljučnega raka, po izbiri nedrobnoceličnega pljučnega raka.
  3. 3. Metoda po katerem koli od predhodnih zahtevkov, kjer mutantni EGFR polipeptid obsega mutacijo v kinazni domeni.
  4. 4. Metoda po katerem koli od predhodnih zahtevkov, kjer odkrivanje prisotnosti polipeptida, ki ima ROS1 kinazno aktivnost obsega uporabo protitelesa.
  5. 5. Metoda po katerem koli od predhodnih zahtevkov, kjer je odkrivanje prisotnosti polinukleotida, ki kodira polipeptid, ki ima ROS1 kinazno aktivnost, obsega uporabo in situ hibridizacije in/ali amplifikacijo nukleinske kisline.
  6. 6. Metoda po katerem koli od predhodnih zahtevkov, kjer odkrivanje prisotnosti mutiranega EGFR polipeptida obsega uporabo mutantno specifičnega protitelesa.
  7. 7. Metoda po katerem koli predhodnem zahtevku, kjer odkrivanje prisotnosti polinukleotida, ki kodira mutantni EGFR polipeptid obsega uporabo nukleinsko kislinskega sekvenciranja.
  8. 8. Metoda po katerem koli predhodnem zahtevku, kjer odkrivanje prisotnosti polinukleotida, ki kodira mutantni EGFR polipeptid obsega uporabo nukleinsko kislinske amplifikacije.
  9. 9. Terapevtsko učinkovita količina ROS1 inhibitorja in EGFR inhibitorja za uporabo pri zdravljenju človeškega pacienta za rakom v metodi, ki obsega: določanje da biološki vzorec iz tumorja pri bolniku obsega ROS1 fuzijski polipeptid, ki ima ROS1 kinazno aktivnost ali polinukleotid, ki kodira isto in mutantni EGFR polipeptid ali polinukleotid, ki kodira isto.
  10. 10. ROS1 inhibitor in EGFR inhibitor za uporabo po zahtevku 9, kjer je tumor pljučni rak, po izbiri nedrobnocelični pljučni rak.
  11. 11. ROS1 inhibitor in EGFR inhibitor za uporabo po zahtevku 9 ali zahtevku 10, kjer mutantni EGFR polipeptid obsega mutacijo v domeni kinaze. 12. R0S1 inhibitor in EGFR inhibitor za uporabo po katerem koli od zahtevkov 9- 11, kjer je ROS1 inhibitor izbran iz skupine, ki jo sestavljajo krizotinib, ASP3026, NVP TAE-684, CH5424802 in AP26113.
  12. 13. ROS1 inhibitor in EGFR inhibitor za uporabo po katerem koli od zahtevkov 9- 12, kjer je EGFR inhibitor izbran iz skupine, ki jo sestavljajo gefitinib, erlotinib, cetuksimab, afatinib, necitumumab, nimotuzumab, PF299804, RO5083945, ABT-806 in AP26113.
SI201330902T 2012-04-18 2013-04-18 Egfr in ros1 pri raku SI2838998T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261635057P 2012-04-18 2012-04-18
US201361787033P 2013-03-15 2013-03-15
EP13778278.5A EP2838998B1 (en) 2012-04-18 2013-04-18 Egfr and ros1 in cancer
PCT/US2013/037139 WO2013158859A1 (en) 2012-04-18 2013-04-18 Egfr and ros1 in cancer

Publications (1)

Publication Number Publication Date
SI2838998T1 true SI2838998T1 (sl) 2018-04-30

Family

ID=49384066

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330902T SI2838998T1 (sl) 2012-04-18 2013-04-18 Egfr in ros1 pri raku

Country Status (10)

Country Link
US (2) US20150056193A1 (sl)
EP (2) EP2838998B1 (sl)
DK (1) DK2838998T3 (sl)
ES (1) ES2655842T3 (sl)
HK (2) HK1206056A1 (sl)
HU (1) HUE037856T2 (sl)
PL (1) PL2838998T3 (sl)
PT (1) PT2838998T (sl)
SI (1) SI2838998T1 (sl)
WO (1) WO2013158859A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
WO2017037220A1 (en) * 2015-09-03 2017-03-09 Ist Austria Ros1 positive cancer treatment
WO2020016266A1 (en) * 2018-07-17 2020-01-23 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021057882A1 (zh) * 2019-09-26 2021-04-01 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4139440A1 (en) 2020-04-22 2023-03-01 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CN113186291B (zh) * 2021-05-26 2022-04-29 嘉兴允英医学检验有限公司 基于多重pcr的引物组和试剂盒

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US416567A (en) 1889-12-03 Ice-cream freezer
US447493A (en) 1891-03-03 Cuff-holder
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2225816T5 (es) 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US7785810B2 (en) 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
JP4095895B2 (ja) 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
JP2005514002A (ja) 2001-05-17 2005-05-19 ザ パブリック ヘルス リサーチ インスティテュート オブ ザ シティ オブ ニューヨーク，インコーポレーテッド Ｒｎａをアンチセンス攻撃するための標的部位の選択
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
JP2006508899A (ja) 2002-05-20 2006-03-16 アブジエニツクス・インコーポレイテツド ＥＧＦｒに対する抗体を使用する腎癌の治療方法
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
MX2009007987A (es) * 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
US20110110923A1 (en) 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2010009392A2 (en) 2008-07-17 2010-01-21 Ocean Nutrition Canada Limited Compositions and methods for increasing microbial production of coenzyme q
CA2744236C (en) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
AU2010339478B2 (en) * 2009-12-31 2014-08-07 Ventana Medical Systems, Inc. Simultaneous detection of mutational status and gene copy number
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
JP5861244B2 (ja) 2010-06-22 2016-02-16 公益財団法人がん研究会 新規ｒｏｓ１融合体の検出法
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers

Also Published As

Publication number Publication date
EP2838998A1 (en) 2015-02-25
EP2838998A4 (en) 2015-10-07
US20150056193A1 (en) 2015-02-26
PL2838998T3 (pl) 2018-04-30
EP3336181A1 (en) 2018-06-20
EP3336181B1 (en) 2022-01-12
HUE037856T2 (hu) 2018-09-28
US20220267854A1 (en) 2022-08-25
ES2655842T3 (es) 2018-02-21
HK1206056A1 (en) 2015-12-31
DK2838998T3 (en) 2018-01-15
PT2838998T (pt) 2018-01-16
EP2838998B1 (en) 2017-10-11
HK1256196A1 (zh) 2019-09-13
WO2013158859A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
SI2838998T1 (sl) Egfr in ros1 pri raku
ATE541946T1 (de) Verfahren und system zur bestimmung von genkopiezahlvarianten
RU2014110228A (ru) Диагностические маркеры
HRP20220496T1 (hr) Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr
Fuh et al. Homologous recombination deficiency real-time clinical assays, ready or not?
JP2014531213A5 (sl)
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
ATE531725T1 (de) Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
NZ610482A (en) Predictors of patient response to treatment with egf receptor inhibitors
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
DE602004030114D1 (de) System zum nachweis von polynukleotiden
JP2016513094A5 (sl)
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
Burrell et al. Re-evaluating clonal dominance in cancer evolution
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
DE602007009954D1 (de) Verfahren zur identifizierung von polypeptid-targets
BRPI0912927A2 (pt) "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
WO2018183817A3 (en) Tumor burden as measured by cell free dna
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
Huemer et al. AID induces intraclonal diversity and genomic damage in CD86+ chronic lymphocytic leukemia cells